

Allen R. Nissenson, MD, FACP
Chief Medical Officer & Senior VP

November 6, 2017

Bryan Becker, MD
Chief Medical Officer, VillageHealth

Jeffrey Giullian, MD, MBA
Chief Medical Officer, DaVita Hospital Services

David Mahoney, MD
Chief Medical Officer, DaVita RMS Lifeline

Robert Provenzano, MD
Chief Medical Officer,
Nephrology Practice Solutions

Martin Schreiber, MD
Chief Medical Officer, DaVita Home Modalities

John Wigneswaran, MD
Chief Medical Officer, DaVita Rx

George Aronoff, MD
VP, Clinical Affairs

Steven Brunelli, MD
VP, Health Economics & Outcomes Research

Mark Kaplan, MD
VP, Medical Affairs

Stephen McMurray, MD
VP, Clinical Integrated Care Management Services

Robert Merrell, MD
VP, Clinical Risk Support

John Robertson, MD
VP, Clinical Support Services

Francesca Tentori, MD
Medical Director, Outcomes Research

David Van Wyck, MD
VP, Clinical Support Services

Adam Weinstein MD
VP, Clinical IT and Architecture

Mahesh Krishnan
MD, MPH, MBA, FASN
Chief Medical Officer, International
Group VP, Research & Development

Abdulkareem Alsuwaida, MD
Chief Medical Officer, KSA

Szymon Brzosko, MD
Chief Medical Officer, Poland

Maciej Drozd, MD
Chief Medical Officer, EMEA

Joao Frazao, MD
Chief Medical Officer, Portugal

Stefan Jacobson, MD
Chief Medical Officer, EMEA

Werner Kleophas, MD
Chief Medical Officer, Germany

Maurilo Leite, MD
Chief Medical Officer, Brazil

Mauricio Ruiz, MD
Chief Medical Officer, Colombia

Suresh Sankar, MD
Chief Medical Officer, India

Rosnawati Yahya, MD
Chief Medical Officer, Malaysia

Grace Yan, MD
Chief Medical Officer, China

Allison Tong
SONG Executive Committee

Dear Allison:

On behalf of DaVita Kidney Care I am pleased to write in support of the SONG initiative. Standardization of outcomes is important in a variety of settings including clinical trials, continuous quality improvement, and when outcomes are reported publically. I think that this work of the global kidney community with inclusion of patients and family members is of great value in these areas.

DaVita Kidney Care supports standardization of trial outcomes because this facilitates comparison of data from different trials and enhances the development of robust clinical practice guidelines.

I agree that your work can improve the relevance and value of trials for informed shared decision-making among patients with chronic kidney disease and their healthcare providers.

DaVita Kidney Care will utilize the SONG results as a resource for future quality metric development and when discussing publically reported data with regulators.

Thank you very much for the excellent work and the service you are doing for the discipline of nephrology and more importantly for patients with kidney disease.

Sincerely,



Allen R. Nissenson, MD, FACP
Chief Medical Officer and Senior Vice President
DaVita Kidney Care